Betul Ibis and colleagues, used the TriNetX database to compare 217,302 diabetes patients on GLP-1 medications with 217,302 matched patients on DPP-4 inhibitors. Patients on GLP-1s had a significantly lower risk of developing rheumatoid arthritis (HR = 0.87, p = 0.026), gout, and osteoarthritis within one year
Related Reading Lifemd Ozempic Eden Ozempic Ro Ozempic Mochi Ozempic Pricing and availability current as of July 2026
Xie et al., 2016), leading to a chronic OS state (Schallreuter, 2014)
Hiu qu ca vin ung trng da cn ph thuc vo c a ca mi ngi, tnh trng da ban u v cc yu t khc nh mi trng sng, ch sinh hot
Why Not Every Day
( GLP-1 RAs recently appearing on the market, in particular liraglutide, semaglutide and tirzepatide (a GIP/GLP-1 RA dual agonist) seek to overcome the problem of the short plasma half-life of native GLP-1 through (i) changing the amino acid sequence of the peptide so that it is no longer broken down by DPP-4, and/or (ii) attaching a long acyl chain to the peptide, thus allowing it to bind to albumin, and avoid rapid elimination via the kidney